Mutation analysis of 24 known cancer genes in the NCI-60 cell line set

被引：361

作者：

Ikediobi, Ogechi N.

Davies, Helen

Bignell, Graham

Edkins, Sarah

Stevens, Claire

O'Meara, Sarah

Santarius, Thomas

Avis, Tim

Barthorpe, Syd

Brackenbury, Lisa

Buck, Gemma

Butler, Adam

Clements, Jody

Cole, Jennifer

Dicks, Ed

Forbes, Simon

Gray, Kristian

Halliday, Kelly

Harrison, Rachel

Hills, Katy

Hinton, Jonathan

Hunter, Chris

Jenkinson, Andy

Jones, David

Kosmidou, Vivienne

Lugg, Richard

Menzies, Andrew

Mironenko, Tatiana

Parker, Adrian

Perry, Janet

Raine, Keiran

Richardson, David

Shepherd, Rebecca

Small, Alex

Smith, Raffaella

Solomon, Helen

Stephens, Philip

Teague, Jon

Tofts, Calli

Varian, Jennifer

Webb, Tony

West, Sofie

Widaa, Sara

Yates, Andy

Reinhold, William

Weinstein, John N.

Stratton, Michael R.

Futreal, P. Andrew

Wooster, Richard

机构：

[1] Wellcome Trust Sanger Inst, Canc Genome Project, Cambridge CB10 1SA, England

[2] Natl Canc Inst, Mol Pharmacol Lab, Genom & Bioinformat Grp, Bethesda, MD USA

[3] Inst Canc Res, Sutton, Surrey, England

来源：

MOLECULAR CANCER THERAPEUTICS | 2006年 / 5卷 / 11期

基金：

英国惠康基金;

关键词：

D O I：

10.1158/1535-7163.MCT-06-0433

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in oncogenesis has been reported. This study reports the sequence analysis of 24 known cancer genes in the NCI-60 and an assessment of 4 of the 24 genes for homozygous deletions. One hundred thirty-seven oncogenic mutations were identified in 14 (APC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, SMAD4, PIK3CA, PTEN, RB1, STK11, TP53, and VHL) of the 24 genes. All lines have at least one mutation among the cancer genes examined, with most lines (73%) having more than one. Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCI-60 cell lines for molecularly targeted screens.

引用

页码：2606 / 2612

页数：7

共 32 条

[1] High-resolution analysis of DNA copy number using oligonucleotide microarrays [J].

Bignell, GR ;

Huang, J ;

Greshock, J ;

Watt, S ;

Butler, A ;

West, S ;

Grigorova, M ;

Jones, KW ;

Wei, W ;

Stratton, MR ;

Futreal, PA ;

Weber, B ;

Shapero, MH ;

Wooster, R .

GENOME RESEARCH, 2004, 14 (02) :287-295

[2] Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel [J].

Bussey, KJ ;

Chin, K ;

Lababidi, S ;

Reimers, M ;

Reinhold, WC ;

Kuo, WL ;

Gwadry, F ;

Jain, A ;

Kouros-Mehr, H ;

Fridlyand, J ;

Jain, A ;

Collins, C ;

Nishizuka, S ;

Tonon, G ;

Roschke, A ;

Gehlhaus, K ;

Kirsch, I ;

Scudiero, DA ;

Gray, JW ;

Weinstein, JN .

MOLECULAR CANCER THERAPEUTICS, 2006, 5 (04) :853-867

[3] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

[4] Somatic mutations of the protein kinase gene family in human lung cancer [J].

Davies, H ;

Hunter, C ;

Smith, R ;

Stephens, P ;

Greenman, C ;

Bignell, G ;

Teague, B ;

Butler, A ;

Edkins, S ;

Stevens, C ;

Parker, A ;

O'Meara, S ;

Avis, T ;

Barthorpe, S ;

Brackenbury, L ;

Buck, G ;

Clements, B ;

Cole, J ;

Dicks, E ;

Edwards, K ;

Forbes, S ;

Gorton, M ;

Gray, K ;

Halliday, K ;

Harrison, R ;

Hills, K ;

Hinton, J ;

Jones, D ;

Kosmidou, V ;

Laman, R ;

Lugg, R ;

Menzies, A ;

Perry, J ;

Petty, R ;

Raine, K ;

Shepherd, R ;

Small, A ;

Solomon, H ;

Stephens, Y ;

Tofts, C ;

Varian, J ;

Webb, A ;

West, S ;

Widaa, S ;

Yates, A ;

Brasseur, F ;

Cooper, CS ;

Flanagan, AM ;

Green, A ;

Knowles, M .

CANCER RESEARCH, 2005, 65 (17) :7591-7595

[5] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[6] A census of human cancer genes [J].

Futreal, PA ;

Coin, L ;

Marshall, M ;

Down, T ;

Hubbard, T ;

Wooster, R ;

Rahman, N ;

Stratton, MR .

NATURE REVIEWS CANCER, 2004, 4 (03) :177-183

[7] Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma [J].

Garraway, LA ;

Widlund, HR ;

Rubin, MA ;

Getz, G ;

Berger, AJ ;

Ramaswamy, S ;

Beroukhim, R ;

Milner, DA ;

Granter, SR ;

Du, JY ;

Lee, C ;

Wagner, SN ;

Li, C ;

Golub, TR ;

Rimm, DL ;

Meyerson, ML ;

Fisher, DE ;

Sellers, WR .

NATURE, 2005, 436 (7047) :117-122

[8] Update on NCI in vitro drug screen utilities [J].

Holbeck, SL .

EUROPEAN JOURNAL OF CANCER, 2004, 40 (06) :785-793

[9] Epidermal growth factor receptor mutations in non-small-cell lung cancer:: Implications for treatment and tumor biology [J].

Jänne, PA ;

Engelman, JA ;

Johnson, BE .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (14) :3227-3234

[10] Targeting the p53-MDM2 interaction to treat cancer [J].

Klein, C ;

Vassilev, LT .

BRITISH JOURNAL OF CANCER, 2004, 91 (08) :1415-1419

← 1 2 3 4 →